钙、维生素D或联合补充预防骨折与跌倒:系统综述与荟萃分析
主要结局任何骨折方面,钙补充(RR 0.91,95%CI 0.81-1.01)、维生素D(RR 1.00,95%CI 0.95-1.06)或联合补充(RR 0.91,95%CI 0.84-0.99)效果甚微至无。基于绝对风险降低和临床意义阈值,补充对骨折和跌倒预防几乎没有益处。
要点
- 钙、维生素D或联合补充对任何骨折风险影响甚微至无。
- 联合补充的RR 0.91(95%CI 0.84-0.99),但绝对风险降低未达临床意义阈值。
- 对其他骨折和跌倒结局同样效果甚微,证据确定性中至高等。
核心结论
- 基于绝对风险降低和临床意义阈值,钙、维生素D或联合补充对骨折和跌倒预防几乎无益处。
研究设计与样本
- 检索Medline、Embase、CENTRAL至2025年2月19日,并检索临床试验注册库、会议摘要和参考文献。
- 87%参与者为社区居住,73%不属于骨折或跌倒高风险人群。
主要发现
- 任何骨折:钙补充11项试验9067人,RR 0.91(95%CI 0.81-1.01),中等确定性。
- 对其他骨折和跌倒结局效果甚微至无,证据确定性中至高等。
- 广泛亚组分析探索异质性后结果稳健。
临床怎么用
- 不应常规以钙、维生素D或联合补充来预防社区成人骨折和跌倒。
- 临床决策需结合绝对风险降低与临床意义阈值,而非仅看相对风险。
局限性
- 高危患者或需住院照护者在多个结局上证据有限,尤其钙单药和联合补充。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effect of calcium, vitamin D, or combined supplementation on fractures and falls in adults. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Trials included in systematic reviews from 2014, three databases (Medline, Embase, CENTRAL) to 19 February 2025, clinical trial registries, abstracts from scientific meetings, and references from included studies. ELIGIBILITY CRITERIA: Randomised controlled trials comparing calcium, vitamin D, or combined supplementation with placebo or no treatment in adults (≥18 years) not receiving drug treatment for osteoporosis. DATA EXTRACTION AND SYNTHESIS: The primary outcome was the risk of any fracture. Secondary outcomes included the risk of hip fracture, non-vertebral fracture, vertebral fracture, and falling, as well as the total number of falls. Pairs of reviewers independently screened trials, extracted data, and assessed risk of bias using the second version of Cochrane's risk of bias tool. Findings were synthesised using random effects meta-analyses and appraised using Grading of Recommendations Assessment, Development and Evaluation, with application of thresholds for absolute effects considered important. RESULTS: This review included 69 trials involving 153 902 participants. Participants in most of the trials were community dwelling (87%) and not at high risk of fractures or falls (73%). For the primary outcome of any fracture, little to no effect was found from use of calcium supplements (11 trials, 9067 participants; risk ratio 0.91, 95% confidence interval 0.81 to 1.01; moderate certainty), vitamin D supplements (36 trials, 92 045 participants; 1.00, 0.95 to 1.06; high certainty), or combined supplementation (15 trials, 51 126 participants; 0.91, 0.84 to 0.99; high certainty). Calcium, vitamin D, or combined supplementation appeared to have little to no effect on other fracture and fall outcomes, based largely on moderate to high certainty of evidence. The findings remained robust after an extensive exploration of heterogeneity across multiple subgroup analyses. Evidence for high risk patients or those requiring residential care was limited for many outcomes for calcium monotherapy and for combined supplementation. CONCLUSION: Based on absolute risk reductions and thresholds considered clinically meaningful, this review found little to no benefits from use of calcium, vitamin D, or combined supplementation on the prevention of fractures and falls. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023483915.
引用
- Massé O, Mercurio CM, Dupuis S, et al. Calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis. BMJ. 2026. PMID: 42161415. doi:10.1136/bmj-2025-088050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。